Explore the Agenda
7:30 am Check In & Morning Coffee
Leveraging Smarter Trial Design to Ensure Accurate Enrolment & Timely Treatment Delivery
8:30 am Panel Discussion: Navigating Patient Selection & Eligibility in Europe to Ensure Timely Access to Cell Therapies
R&D Track
Innovaiton in Science
Innovating in Receptor Designs & Novel Targets to Increase Efficacy in Difficult Indications
11:30 am Advancing Next-Generation TCR Therapies Targeting ROPN1 to Address Triple-Negative Breast Cancer
12:00 pm Development of TCR Technology Platforms for Cancer Immunotherapy
Manufacturing Track
Realising Scale & Access
Overcoming Analytical Bottlenecks for Reliable Product Release
11:30 am Reserved for Klinea Biotech & Pharma Engineering
11:40 am Standardising CAR T-Cell Monitoring to Improve Clinical Insights & Translational Outcomes
12:30 pm Lunch & Networking Break
R&D Track
Innovaiton in Science
Leveraging Armouring & Combination Approaches to Overcome Solid Tumour Barriers & Unlock Durable Responses
1:30 pm CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity
2:00 pm STAb-T Cells: Bridging Cell Therapy & Bispecific Antibodies for Sustained Antitumour Immunity
Manufacturing Track
Realising Scale & Access
Driving Lean Manufacturing to Reduce Costs & Accelerate Timelines
1:30 pm Panel Discussion: Manufacturing Leaner & More Affordably to Accelerate Cell Therapy Development in Europe
2:00 pm Driving Efficiency & Unlocking Scalability for PRAME Cell Therapy Manufacturing
R&D Track Innovation & Science
Innovating in Receptor Designs & Novel Targets to Increase Efficacy in Difficult Indications
11:30 am Advancing Next-Generation TCR Therapies Targeting ROPN1 to Address Triple-Negative Breast Cancer
12:00 pm Development of TCR Technology Platforms for Cancer Immunotherapy
Manufacturing Track Realising Scale & Access
Track Name
Track Name
12:30 pm Lunch & Networking Break
R&D Track Innovation & Science
Leveraging Armouring & Combination Approaches to Overcome Solid Tumour Barriers & Unlock Durable Responses
1:30 pm CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity
2:00 pm STAb-T Cells: Bridging Cell Therapy & Bispecific Antibodies for Sustained Antitumour Immunity
Manufacturing Track Realising Scale & Access
Track Name
Track Name